Johnson & Johnson · NYSE:JNJ
Johnson & Johnson — Merger or Acquisition (November 2022)
22 slides from Johnson & Johnson's merger presentation, Nov 1, 2022
Slide 1: Johnson & Johnson Announces Acquisition of Abiomed
Johnson & Johnson Announces Acquisition of Abiomed Conference Call to Begin at 8:00 AM ET 1
Slide 2: Johnson & Johnson + Abiomed Investor Presentation
Johnson & Johnson + Abiomed Investor Presentation November 1, 2022 2
Slide 3: Today's Speakers
Today’s Speakers Joaquin Duato Ashley McEvoy Joe Wolk Michael Minogue Chief Executive Officer of Executive Vice President and Chief Financial Officer of Chairman, President and Johnson & Johnson Worldwide Chairman of Johnson & Johnson Chief Executive Officer of MedTech at Johnson & Abiomed Johnson 3
Slide 4: Cautionary Note on Forward Looking Statements
Cautionary Note on Forward Looking Statements This presentation contains forward-looking statements regarding the potential acquisition of ABIOMED. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underly
Slide 5: Joaquin Duato
Joaquin Duato Chief Executive Officer, Johnson & Johnson 5
Slide 6: Addressing the Most Challenging Diseases in Healthcare
Addressing the Most Challenging Diseases in Healthcare Focus on scientific R&D Mission of addressing major Focus on patient unmet medical needs and disease-centric care Demand for Global Delivering Understanding Life-Enhancing Leading-Edge that Good Innovations at Technology Health is the Speed and
Slide 7: Advancing Mission to Make Heart Recovery the Standard of Care
Advancing Mission to Make Heart Recovery the Standard of Care Right transaction, right partner, right time Operating a safe, reliable, regulated Educating customers Strengthening natural gas business Funding clean, Promoting a culture of about the emissions relationships with our with world-class re
Slide 8: Our Credo
Nuestro Credo Le To Miotew pag sence bv apn eg 0 Our Credo kamen nd se ‘nitions Dy ‘Ne beter tapas toe pte, dst rd on at eens nein tema mn ‘rans, to moter and father an a others who use our products pa = anal chive prrecea _and services. In mesting their needs everything we do must be of ala a = ~ i
Slide 9: Michael Minogue
Michael Minogue Chairman, President and Chief Executive Officer, Abiomed 9
Slide 10: Abiomed Overview
Abiomed Overview Leading provider of groundbreaking medical technology that provides circulatory and oxygenation support 1981 Founded 18 year Track record of profitable growth 2,200+ Employees Headquartered in Danvers, Massachusetts Abiomed Breethe Robust Pipeline of Impella® Heart Pump ✓ FDA grante
Slide 11: Ashley McEvoy
Ashley McEvoy Executive Vice President and Worldwide Chairman of MedTech, Johnson & Johnson 11
Slide 12: Diversifies and Expands Portfolio in High Growth Market
Biosurgery Surgical Vision Trauma Diversifies and Contact Lenses Expands Portfolio Electrophysiology JJMT in High Growth Heart Recovery Energy + Heart Recovery Market Endocutters Knees Extends Portfolio to 12 $1B+ Platforms Sutures Hips Spine 12
Slide 13: Heart failure is one of the largest unmet needs
Within cardiovascular, HEART FAILURE is one of the largest unmet needs for all stakeholders: $70B 26M Cardiovascular disease is the #1 direct medical costs total patients worldwide cause of death #1 ALL #1 hospital cardiac mortality risk forms of cardiovascular disease lead cause of hospitalizations
Slide 14: Addressing a >$35 Billion U.S. Market Opportunity
Addressing a >$35 Billion U.S. Market Opportunity Protected (High Risk) Cardiogenic Respiratory Failure Heart Heart Attack PCI Shock (ECMO) Failure (STEMI) FDA Approval or 510(k) FDA Approval or 510(k) FDA Approval or 510(k) FDA Approval or 510(k) FDA PMA Clearance Clearance Clearance Clearance Stud
Slide 15: Adds Robust Platform and Pipeline for Long-term Innovation
Adds Robust Platform and Pipeline for Long-term Innovation Impella ECP™ preCARDIA™ Impella BTR™ • 9 Fr catheter & pump at insertion and removal; • Therapy for acutely decompensating heart • Minimally invasive, durable heart pump ideal for high-risk PCI failure with superior vena-cava occlusion desig
Slide 16: Leveraging Johnson & Johnson's Capabilities
Leveraging Johnson & Johnson’s Capabilities Expansive Leading Physician Global Footprint Education Capabilities Commercial Excellence Robust Clinical Expertise 16
Slide 17: Joe Wolk
Joe Wolk Chief Financial Officer, Johnson & Johnson 17
Slide 18: Value-Creating Transaction
Value-Creating Transaction Accelerates Revenue Accretive to EPS1 Growth1 Accelerate pro forma Slightly dilutive to Accretive by MedTech and Johnson & neutral to Johnson & approximately $0.05 Johnson revenue growth Johnson’s adjusted in 2024 and earnings per share in increasingly 2023 accretive there
Slide 19: Transaction Details and Path to Close
Transaction Details and Path to Close Expected to close prior to the end of the first quarter of 2023 Purchase Price and • $380.00 per share in cash upfront Contingent Value • ~$16.6 billion enterprise value1 Right (CVR) Structure • One non-tradeable CVR up to an additional $35.00 per share in cash
Slide 20: Johnson & Johnson + Abiomed Highlights
Johnson & Johnson + Abiomed Highlights Brings lifesaving Aligns with Johnson & innovations to more patients Johnson strategic priorities with unmet needs Accelerates growth of Compelling for both Abiomed Johnson & Johnson MedTech and Johnson & Johnson shareholders 20
Slide 21: Questions
Questions 21
Slide 22: Thank You
Thank You 22
Johnson & Johnson — Merger or Acquisition (November 2022) on 6ix